135 related articles for article (PubMed ID: 16520652)
1. Managing locally advanced prostate cancer: a urologist's and a patient's perspective.
Kirby R; Offen N
Anticancer Drugs; 2006 Mar; 17(3):245-50. PubMed ID: 16520652
[TBL] [Abstract][Full Text] [Related]
2. Locally advanced prostate cancer treated with radiotherapy and androgen deprivation.
Kirby R
Nat Clin Pract Urol; 2005 Jun; 2(6):304-8. PubMed ID: 16474813
[TBL] [Abstract][Full Text] [Related]
3. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
See WA; Tyrrell CJ;
J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
[TBL] [Abstract][Full Text] [Related]
4. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
[TBL] [Abstract][Full Text] [Related]
5. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
Nyman CR; Andersen JT; Lodding P; Sandin T; Varenhorst E
BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
[TBL] [Abstract][Full Text] [Related]
6. Bicalutamide treatment for locally advanced prostate cancer.
Anderson J
Hosp Med; 2000 Sep; 61(9):660-3. PubMed ID: 11048610
[TBL] [Abstract][Full Text] [Related]
7. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
Tyrrell CJ; Payne H; See WA; McLeod DG; Wirth MP; Iversen P; Armstrong J; Morris C;
Radiother Oncol; 2005 Jul; 76(1):4-10. PubMed ID: 16145740
[TBL] [Abstract][Full Text] [Related]
8. Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.
Wellington K; Keam SJ
Drugs; 2006; 66(6):837-50. PubMed ID: 16706554
[TBL] [Abstract][Full Text] [Related]
9. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
Wirth M; Tyrrell C; Wallace M; Delaere KP; Sánchez-Chapado M; Ramon J; Hetherington J; Pina F; Heynes CF; Borchers TM; Morris T; Stone A
Urology; 2001 Aug; 58(2):146-51. PubMed ID: 11489683
[TBL] [Abstract][Full Text] [Related]
10. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
[TBL] [Abstract][Full Text] [Related]
11. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.
Sternberg CN
BJU Int; 2006 Mar; 97(3):435-8. PubMed ID: 16469001
[No Abstract] [Full Text] [Related]
12. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program.
Brawer MK
BJU Int; 2003 Apr; 91(6):465-6. PubMed ID: 12656893
[No Abstract] [Full Text] [Related]
13. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
Tyrrell CJ; Kaisary AV; Iversen P; Anderson JB; Baert L; Tammela T; Chamberlain M; Webster A; Blackledge G
Eur Urol; 1998; 33(5):447-56. PubMed ID: 9643663
[TBL] [Abstract][Full Text] [Related]
14. Treatment of locally advanced prostate cancer--a new role for antiandrogen monotherapy?
Abrahamsson PA
Eur Urol; 2001; 39 Suppl 1():22-8. PubMed ID: 11114597
[TBL] [Abstract][Full Text] [Related]
15. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
See WA; Wirth MP; McLeod DG; Iversen P; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Vaage S; Tammela TL; Lukkarinen O; Persson BE; Carroll K; Kolvenbag GJ;
J Urol; 2002 Aug; 168(2):429-35. PubMed ID: 12131282
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).
Kucuk O; Fisher E; Moinpour CM; Coleman D; Hussain MH; Sartor AO; Chatta GS; Lowe BA; Eisenberger MA; Crawford ED
Urology; 2001 Jul; 58(1):53-8. PubMed ID: 11445479
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant hormonal treatment for prostate cancer: the bicalutamide early prostate cancer program.
Wirth MP; Froehner M
Oncology; 2003; 65 Suppl 1():1-4. PubMed ID: 12949426
[TBL] [Abstract][Full Text] [Related]
18. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
Martorana G
Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
[No Abstract] [Full Text] [Related]
19. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
[TBL] [Abstract][Full Text] [Related]
20. [Reevaluation of MAB therapy and progress of endocrine therapy].
Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
[No Abstract] [Full Text] [Related]
[Next] [New Search]